Petros Pharmaceuticals Inc (PTPI)
0.53
-0.06
(-9.86%)
USD |
NASDAQ |
May 15, 14:41
Petros Pharmaceuticals Research and Development Expense (Quarterly): 0.8343M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.8343M |
| September 30, 2023 | 0.3891M |
| June 30, 2023 | 0.8666M |
| March 31, 2023 | 0.3191M |
| December 31, 2022 | 0.1778M |
| September 30, 2022 | 0.7359M |
| June 30, 2022 | 0.4212M |
| March 31, 2022 | 0.4054M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.9887M |
| September 30, 2021 | 0.2806M |
| June 30, 2021 | 0.50M |
| March 31, 2021 | 0.0192M |
| December 31, 2020 | 0.1518M |
| September 30, 2020 | 0.0368M |
| June 30, 2020 | 0.1316M |
| March 31, 2020 | 0.1394M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.0192M
Minimum
Mar 2021
0.9887M
Maximum
Dec 2021
0.3998M
Average
0.3541M
Median
Research and Development Expense (Quarterly) Benchmarks
| Avalo Therapeutics Inc | 1.867M |
| Imunon Inc | 3.553M |
| iBio Inc | 1.535M |
| Oramed Pharmaceuticals Inc | 1.179M |
| Ocugen Inc | 9.504M |